Global Chronic Kidney Disease Market Analysis 2018 - Extensive Study on the Marketed, Clinical and Preclinical Molecules Available/Being Developed for the Treatment of Chronic Kidney Disease

DUBLIN, Dec. 12, 2018 /PRNewswire/ --

The "Chronic Kidney Disease Market: Pipeline Review, Developer Landscape and Competitive Insights" report has been added to ResearchAndMarkets.com's offering.

Chronic Kidney Disease Market: Pipeline Review, Developer Landscape, and Competitive Insights

provides an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of chronic kidney disease.

Chronic kidney disease (CKD) is characterized by progressive loss of kidney function over a period of time. In most patients suffering from CKD, symptoms (such as swollen ankles, blood in urine and foamy urine) are rarely observed until kidney function has declined by 75%. It is worth highlighting that over 90% of the patients suffering from reduced kidney function are unaware of their medical condition.

In the US, 15% of adults are reported to be suffering from mild or severe forms of CKD. In fact, the mean global prevalence of CKD, across all five stages of the disease, is estimated to be 13.4%.

Limited availability of epidemiological data, lack of awareness, late diagnosis and inappropriate/incorrect treatment are some of the factors responsible for elevating disease incidence. It is also worth noting that developed nations spend over 2-3% of their annual healthcare budget on the treatment of end-stage renal disease (ESRD); however, the economic burden associated with milder forms of CKD is almost double the total costs incurred in the treatment of ESRD.

Further, in the US, the disease has been estimated to incur combined direct and indirect costs ranging between USD 1,183 - USD 35,292 per patient, per month.

Existing therapeutic options have already been proven to be inadequate in containing the progression of the disease and its symptoms in the long term.

Currently, several stakeholders in the pharmaceutical industry are engaged in efforts to advance the development of various types of disease-modifying pharmacological interventions and therapies that offer symptomatic relief. In fact, multiple initiatives by start-ups are being backed by venture capital funding in order to expedite the development of potential therapeutic options for better disease management.

Key Highlights

• The analysis of content presented on informal (100 patient blogs and over 3,000 social media posts) and formal (180 scientific articles) literary sources, and the opinions expressed by industry experts confirm the existence of a significant unmet need within the chronic kidney disease market. Some of the unaddressed concerns suggested across multiple portals include improved therapeutic strategies, better management of comorbidities, lack of awareness related to the conditions leading to chronic kidney disease, high economic burden, unavailability of dialysis centers and poor quality of life.
• Presently, over 160 product candidates are being evaluated across various stages of development for the management/treatment of chronic kidney disease. Of these, 24% are in the preclinical or discovery phase. Amongst the drugs that are under clinical development, 33 are in phase III / pre-registration, 47 in phase II, and 22 in phase I and phase I/II trials. Interestingly, since 2012, 22 product candidates have been commercialized; examples include JYNARQUE (2018), Parsabiv (2017), RAYALDEE (2016) and VELTASSA (2015).
• Majority of novel drug candidates (close to 70%) are disease-modifying agents, while nearly 30% designed to provide symptomatic relief only. It is worth highlighting that 75% of pipeline candidates are small molecules, and the rest are biologics. Further, most are being developed as monotherapies (close to 75%), whereas nearly 25% are currently being investigated as combination therapies.
• The market landscape is characterized by the presence of large (31), mid-sized (33) and small-sized companies (47). Examples of prominent large companies engaged in this domain include (in alphabetical order, no selection criteria) Amgen, Asahi Kasei Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Merck Sharp & Dohme, Novartis Pharmaceuticals, Pfizer and Sanofi. The growing unmet need within this domain has spurred the establishment of many start-ups / small-sized companies in recent years; examples include (in alphabetical order, no selection criteria) Algomedix, Angion Biomedica, Anthera Pharmaceuticals, Apellis Pharmaceuticals, Complexa, Ember Therapeutics, Genkyotex, Goldfinch Bio, inRegen, Kezar Life Sciences, Lanthio Pharma, Orbis Biosciences, Redx pharma, Sanifit, and Serodus.
• Stakeholders in the industry have forged several strategic partnerships in the recent past; we observed that 28% of the agreements that were signed between 2015 and 2018 were related to research and development. These were followed by development and commercialization agreements (23%), licensing agreements (22%), commercialization agreements (15%), acquisitions (5%), mergers (5%), and manufacturing agreements (2%). Examples of recently inked deals include collaborations between Novo Nordisk and Evotec (August 2018), Resverlogix and Medison Pharma (January 2018), and AstraZeneca and Ionis Pharmaceuticals (February 2018).
• Drug development initiatives by start-ups have received financial support in terms of venture funding and research grants. In fact, more than USD 4.1 billion, across 118 instances of grants, venture capital rounds, and public offerings, has been invested in these companies since 2010. Across all the funding rounds, the most active investors include (in terms of participation in funding rounds) Omega Funds, Flagship Pioneering, Polaris Partners, venBio Select, Oxford Finance, OrbiMed Advisors, Morningside Group, Limulus Venture Partners, Cormorant Asset Management, AJU IB Investment, and Sibling Capital.
• Several prominent scientists (over 100) have made significant contributions in advancing the clinical development efforts, and therefore, have emerged as key opinion leaders in this field. Examples of prominent universities and hospitals that have been engaged in conducting breakthrough research in this domain include (in alphabetical order, no selection criteria) Icahn School of Medicine, UC San Diego School of Medicine, University of Michigan, University of Oxford and Vanderbilt University Medical Center.

Key Topics Covered

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Chapter Overview
3.2. An Overview of Chronic Kidney Diseases
3.2.1. Medical Conditions Associated with Chronic Kidney Diseases
3.2.1.1. Alport Syndrome
3.2.1.2. Diabetic Nephropathy
3.2.1.3. Focal Segmental Glomerulosclerosis
3.2.1.4. Glomerulonephritis
3.2.1.5. Nephrotic Syndrome
3.2.1.6. Polycystic Kidney Disease
3.2.1.7. Hypertensive Kidney Disease
3.2.1.8. Pyelonephritis
3.2.2. Stages of Chronic Kidney Disease
3.2.3. Symptoms
3.2.4. Diagnosis
3.2.5. Treatment Options
3.2.5.1. Therapeutics
3.2.5.2. Other Modalities
3.2.7. Kidney Transplant and Implications

4. Pipeline Review: Marketed And Development Drugs
4.1. Chapter Overview
4.2. Drugs for Chronic Kidney Disease: Marketed and Development Pipeline
4.3. Chronic Kidney Disease: Pipeline Analysis
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Route of Administration
4.3.4. Analysis by Target Therapeutic Indication(s)
4.3.5. Analysis by Size of Developer
4.3.6. Analysis by Size and Location of the Players
4.3.7. Analysis of Leading Developers
4.3.8. Heptagon Representation: Distribution by Target Therapeutic Indication and Phase of Development
4.3.9. Grid Analysis: Distribution by Target Therapeutic Indication, Dosing Frequency and Phase of Development
4.3.10. Geographical Landscape

5. Product Clinical Commercial Attractiveness
5.1. Chapter Overview
5.2. Methodology
5.2.1. Assumptions and Key Parameters
5.3. Affiliated Insights

6. Chronic Kidney Disease: Unmet Needs Analysis
6.1. Chapter Overview
6.2. Unmet Needs Analysis in Chronic Kidney Disease
6.2.1. Unmet Needs Expressed in Patient Blogs
6.2.1.1. Methodology
6.2.1.2. Key Insights
6.2.2. Unmet Needs Reported in Published Literature
6.2.2.1. Methodology
6.2.2.2. Key Insights
6.2.3. Unmet Needs Expressed on Social Media Platforms
6.2.3.1. Methodology
6.2.3.2. Key Insights
6.2.4. Unmet Needs Highlighted by Experts
6.2.4.1. Titte Srinivas, Intermountain Medical Centre
6.2.4.2. Brian Clement, Hippocrates Health Institute
6.2.4.3. Frank Brennan, Palliative Care Physician
6.2.4.4. Sarah Brook, Renal Dietitian, Salford Royal NHS Foundation Trust
6.2.4.5. Joseph Selvanayagam, Medical Researcher, Flinders University
6.2.4.6. Vanessa Rojas-Bautista, UC Irvine Health
6.2.5. Concluding Remarks: Key Unmet Needs in Chronic Kidney Disease

7. Company Competitiveness Analysis
7.1. Chapter Overview
7.2. Methodology
7.2.1. Assumptions and Key Parameters
7.3. Company Competitiveness Analysis: Key Insights
7.3.1. Key Players: North America
7.3.2. Key Players: Europe
7.3.3. Key Players: Asia Pacific

8. KOL Analysis
8.1. Chapter Overview
8.2. Methodology
8.3. Principal Investigators Involved in Clinical Trials
8.4. Prominent Key Opinion Leaders
8.5. Most Active Key Opinion Leaders

9. Partnerships and Collaborations
9.1. Chapter Overview
9.2. Partnership Models
9.3. Novel Therapeutics for Chronic Kidney Disease: List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnerships
9.3.2. Analysis by Type of Partnership
9.3.3. Most Active Players: Analysis by Number of Partnerships
9.3.4. Regional Analysis
9.3.4.1. Intercontinental and Intracontinental Agreements

10. Funding And Investment Analysis
10.1. Chapter Overview
10.2. Types of Funding
10.3. Novel Therapeutics for Chronic Kidney Disease: Funding and Investment Analysis
10.3.1. Analysis by Number of Instances
10.3.2. Analysis by Amount Invested
10.3.3. Analysis by Type of Funding
10.3.4. Most Active Players
10.3.5. Most Active Investors
10.4. Concluding Remarks

Companies Featured

• Aarhus University
• Achillion Pharmaceuticals
• Advantech Capital
• AJU IB Investment
• Akebia Therapeutics
• Albany College of Pharmacy and Health Sciences
• Alexandria Venture Investments
• Alexion Pharmaceuticals
• Algomedix
• Allegheny Financial Group
• Amgen
• Amyndas Pharmaceuticals
• Angion Biomedica
• Anthera Pharmaceuticals
• apceth Biopharma
• Apellis Pharmaceuticals
• Apollo Hospitals
• AptaBio Therapeutics
• Ardelyx
• Armetheon
• Asahi Kasei Pharma
• Astellas Pharma
• AstraZeneca
• Aurinia Pharmaceuticals
• Avexxin
• Barclays Bank
• Bay City Capital
• Bayer
• Baylor College of Medicine
• Beijing Anzhen Hospital
• Bichat-Claude Bernard Hospital
• Bill & Melinda Gates Foundation
• BIOCAD
• BioVirtus
• BLR Bio
• Boehringer Ingelheim
• Boryung Pharmaceutical
• Bristol-Myers Squibb
• California Institute of Renal Research
• Calliditas Therapeutics
• Cara Therapeutics
• CARB-X
• Cash Capital
• Cedars-Sinai Medical Center
• Celgene
• Cellmid
• Centre Hospitalier Universitaire
• ChemoCentryx
• Children's Mercy Hospital
• China Medical University Hospital
• Chugai Pharmaceutical
• Clough Capital
• Complexa
• Concert Pharmaceuticals
• Cormorant Asset Management
• Cowen Healthcare Investments
• Cowin Capital Group
• Creighton University
• CTI Life Sciences Fund
• CuraGen
• Cycad Group
• Daiichi Sankyo
• DaVita Clinical Research
• DiaMedica Therapeutics
• Dimerix
• Dong-A ST
• Dongguk University
• Duke University
• Dynavax Technologies
• Eastern Capital
• EcoR1 Capital
• Edmond de Rothschild Investment Partners
• Efung Capital
• Ege University
• ElexoPharm
• Eli Lilly and Company
• Elite Capital
• Ember Therapeutics
• Epidarex Capital
• Epigen Biosciences
• Espero BioPharma
• Evanston Northwestern Hospital
• Evotec
• F-Prime Capital Partners
• Flagship Pioneering
• Foresee Pharmaceuticals
• Fosun Pharma
• Fresenius Medical Care
• Fudan University
• Gabriele d'Annunzio' University
• Galectin Therapeutics
• Galencia
• Gazi University
• Genentech
• Genexine
• Genkyotex
• George Washington University
• Georgetown University
• Gilead Sciences
• GlaxoSmithKline
• Glycadia Pharmaceuticals
• GNI Group
• Goldfinch Bio
• Goldman Sachs
• Gujarat Kidney Foundation
• H.C. Wainwright
• Hadassah Medical Center
• Hamad Medical
• Hanmi Pharmaceutical
• Hansa Medical
• HBM Healthcare Investments
• Heidelberg University
• Hennepin Healthcare
• Hercules Capital
• Hermed Capital
• Hoffmann-La Roche
• Hospital Aleman
• Human Genome Sciences
• Hydra Biosciences
• Icahn School of Medicine at Mount Sinai
• Idera Pharmaceuticals
• Indiana University
• Innovation Network Corporation of Japan
• Inositec
• inRegen
• Inselspital
• Ionis Pharmaceuticals
• Iran University of Medical Sciences
• Ironwood Pharmaceuticals
• Italian Hospital
• JAFCO
• Janssen Pharmaceuticals
• Japan Tobacco International
• Jiangsu Maslech Medical Technology
• Johns Hopkins University
• JPMorgan Chase
• Kadmon
• KAI Pharmaceuticals
• KBP Biosciences
• Keryx Biopharmaceuticals
• Kezar Life Sciences
• King's College London
• KISSEI Pharmaceutical
• Klotho Therapeutics
• Knight Therapeutics
• Konkuk University
• Korea Investment Partners
• Kyowa Hakko Kirin
• Kyung Hee University
• L&F Research
• La Jolla Pharmaceutical
• Lanthio Pharma
• Lawson Health Research Institute
• LCR Clinical Research
• Lexicon Pharmaceuticals
• LG Life Sciences
• Limulus Venture Partners
• London Health Sciences Centre
• Longitude Capital
• Lonza
• Mallinckrodt Pharmaceuticals
• Mannkind Corporation
• Mariel Therapeutics
• Maruishi Pharmaceutical
• Massachusetts General Hospital
• Mayo Clinic
• McMaster University
• Medical University of Graz
• Medicxi Ventures
• MedImmune
• Medipal Holdings
• Medison Pharma
• Megapharm
• Merck Serono
• Merck Sharp & Dohme
• Michigan State University
• Mission Therapeutics
• Mitsubishi Tanabe Pharma
• Morningside Ventures
• MRL Ventures Fund
• National Taiwan University Hospital
• Necker-Enfants Malades Hospital
• Nephrotic Syndrome Study Network
• New Enterprise Associates
• NorthShore University HealthSystem
• Novadiol
• Novartis Institutes for Biomedical Research
• Novartis Pharmaceuticals
• Novo Nordisk
• NOXXON Pharma
• Omega Funds
• OPKO Health
• Orange County Research Center
• Oraxion Therapeutics
• OrbiMed
• Orbis Biosciences
• Oregon Health & Science University
• Otsuka Pharmaceuticals
• Ottawa Hospital Research Institute
• Oxford Finance
• Palladio Biosciences
• Pappas Ventures
• Paranta Biosciences
• Pfizer
• Pfizer Venture Investments
• Pharmacosmos
• Ping An Ventures
• PKD Foundation
• Polaris Partners
• Prometic Life Sciences
• Proteomics International
• Proteon Therapeutics
• Qiming Venture Partners
• Queen Mary's Hospital
• Reata Pharmaceuticals
• Redx Pharma
• Regulus Therapeutics
• Relypsa
• Resverlogix
• Retrophin
• Rigel Pharmaceuticals
• Roche
• Rockwell Medical
• Sahlgrenska University Hospital
• Samsung Medical Center
• Sandoz
• Sangel Capital
• Sanifit
• Sanofi
• SCOHIA PHARMA
• SDIC Venture Capital
• Sectoral Asset Management
• Seoul National University
• Seoul St. Mary's Hospital
• Serodus
• Serum Institute of India
• Severance Hospital
• Shenyang Sunshine Pharmaceutical
• Shenzhen Hepalink Pharmaceutical
• Shield Therapeutics
• Sibling Capital Ventures
• Silicon Valley Bank
• Silver Creek Pharmaceuticals
• SK Group
• Sofinnova Ventures
• St. George's University
• Stanford University
• Sumitomo Dainippon Pharma
• Taipei Medical University
• Taisho Pharmaceutical
• Takeda Pharmaceuticals
• Teijin Pharma
• Tel Aviv Sourasky Medical Center
• The George Institute for Global Health
• The Medical University of South Carolina
• The Rogosin Institute
• The University of Alabama
• The University of British Columbia
• Theravance Biopharma
• Third Rock Ventures
• Thynk Capital
• Tokai University
• Toronto General Hospital
• TR-Pharm
• Trevi Therapeutics
• Tricida
• Trisaq
• Tufts Medical Center
• UC San Diego School of Medicine
• UnicoCell Biomed
• Unicyte
• University Hospital Bonn
• University Hospital Center De Montpellier
• University Hospitals Birmingham
• University of Calgary
• University of California
• University of Cincinnati
• University of Frankfurt
• University of Giessen
• University of Guadalajara
• University of Illinois
• University of Kentucky
• University of Leeds
• University of Louisville
• University of Manitoba
• University of Maryland
• University of Michigan
• University of Minnesota
• University of Missouri
• University of Montreal
• University of North Carolina
• University of Oklahoma
• University of Oxford
• University of Pennsylvania
• University of Ulsan
• University of Utah
• University of Wisconsin
• University of Zurich
• Uppsala University Hospital
• Vanderbilt University Medical Center
• Variant Pharmaceuticals
• venBio Global Strategic Fund
• venBio Select
• Venrock Healthcare Capital Partners
• Verily Life Sciences
• Vertex Venture Holdings
• Vidasym
• Vifor Fresenius Medical Care Renal Pharma
• Vifor Pharma
• Visterra
• Vivo Capital
• Washington University School of Medicine
• Watson Laboratories
• Wellington Management
• XORTX Therapeutics
• Yuhan Corporation
• Zeria Pharmaceutical
• ZS Pharma

For more information about this report visit https://www.researchandmarkets.com/research/p5j7mw/global_chronic?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com